Welcome to our dedicated page for Prelude Therapeutics SEC filings (Ticker: PRLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company. Through these regulatory documents, investors can review how Prelude describes its business, pipeline, risks, and financial condition as it advances programs such as SMARCA2 and KAT6A degraders, mutant selective JAK2V617F JH2 inhibitors for myeloproliferative neoplasms, and mutant CALR-targeted degrader antibody conjugates (DACs).
Key filings include annual reports on Form 10-K, which provide an overview of Prelude’s precision oncology strategy, target selection, collaborations, and risk factors, and quarterly reports on Form 10-Q, which update on operating expenses, cash runway, and development progress. Current reports on Form 8-K disclose material events such as the exclusive option agreement with Incyte for the JAK2V617F program, expanded arrangements with AbCellera Biologics, clinical portfolio reprioritizations, Nasdaq listing compliance updates, and changes in board or executive roles.
Investors interested in ownership and governance can also use SEC filings to track equity financings, non-voting common stock issuances, and other capital structure changes described in transaction-related 8-Ks and registration statements. These documents outline terms of option agreements, securities purchase agreements, and related registration rights for Prelude’s stock.
On Stock Titan, each new PRLD filing is captured from EDGAR and paired with AI-powered summaries that highlight the most relevant points, such as pipeline focus, collaboration economics, cash position commentary, and listing status updates. This helps readers navigate lengthy reports and quickly locate information on topics like JAK2V617F program economics, SMARCA2 and KAT6A development plans, and the impact of strategic decisions on Prelude’s financial profile.
Use this page to access Prelude Therapeutics’ 10-K, 10-Q, 8-K and related filings, along with concise AI explanations that clarify technical disclosures and regulatory language for PRLD stock watchers.
Prelude Therapeutics has regained compliance with Nasdaq’s minimum bid price rule. Nasdaq notified the company on September 18, 2025 that its common stock once again meets the $1.00 per share minimum bid price requirement under Listing Rule 5550(a)(2).
This resolves the earlier deficiency notice received in March 2025 and closes the matter, removing the immediate risk of non-compliance with Nasdaq’s continued listing standards for the company’s common stock.
Prelude Therapeutics reported continued operating losses while advancing multiple oncology programs and managing liquidity constraints. For the six months ended June 30, 2025, the company recorded a $63.3 million net loss and had an accumulated deficit of $646.9 million. At June 30, 2025, cash, cash equivalents, restricted cash and marketable securities totaled $77.3 million, but management states these funds are insufficient to cover at least the next twelve months absent additional financing, and substantial doubt exists about the company’s ability to continue as a going concern.
Operationally, R&D and G&A decreased year-over-year to $54.6 million and $12.2 million for the six months, respectively, as clinical expenses and stock-based compensation moderated. Key program milestones include ongoing Phase 1/2 activity for SMARCA2 degraders (PRT3789 and oral PRT7732) and collaborations with AbCellera and Merck. The company also received a Nasdaq bid price deficiency notice with an initial compliance period through September 23, 2025, and maintains a $400 million shelf registration and a $75 million sales agreement capacity that could support future financing.
Prelude Therapeutics furnished a press release disclosing its financial results for the three months ended June 30, 2025, which is attached to this report as Exhibit 99.1. Management also prepared investor presentation materials intended for use in investor presentations and attached those materials as Exhibit 99.2. The filing notes an interactive data file is included as Exhibit 104.
The report emphasizes that the press release and presentation are being furnished, not filed, and therefore are not incorporated by reference into the company’s other securities filings. The 8-K itself does not include the underlying financial figures in its body; readers must review Exhibit 99.1 for the detailed results. The form is signed on the company’s behalf by Bryant Lim, Chief Legal Officer, Corporate Secretary, and Chief Financial Officer.